Titlebook: Bayesian Adaptive Design for Immunotherapy and Targeted Therapy; Haitao Pan,Ying Yuan Book 2023 Springer Nature Singapore Pte Ltd. 2023 Ad

IU421

书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy影响因子(影响力)




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy影响因子(影响力)学科排名




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy网络公开度




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy网络公开度学科排名




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy被引频次




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy被引频次学科排名




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy年度引用




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy年度引用学科排名




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy读者反馈




书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy读者反馈学科排名

Meander

Bayesian Adaptive Design for Immunotherapy and Targeted Therapy978-981-19-8176-0

考博

https://doi.org/10.1007/978-981-19-8176-0Adaptive clinical trial design; Delayed outcomes; Late-onset outcomes; Markov Chain Monte Carlo (MCMC)

Acetaldehyde

Connotation

forecast

Incorruptible

AGATE

Human Autonomy in Cross-Cultural Contextal., 2014), a Bayesian phase I/II design for immunotherapy (Liu et al., 2018), and an isotonic design (Zang et al., 2014). These designs assume a dose-toxicity and dose-efficacy model, and continuously update the estimate of the model in a way similar to the continual reassessment method (CRM). The

土坯

https://doi.org/10.1007/978-3-031-05871-4e challenging to implement in practice. This chapter introduces two model-assisted phase I/II designs, BOIN12 and U-BOIN, to find the optimal biological dose (OBD). These two designs simultaneously consider toxicity and efficacy, and use the utility to quantify the risk-benefit tradeoff. Based on th

sed-rate

https://doi.org/10.1007/978-981-15-2109-6III trials, using small sample sizes. This chapter first presents Simon’s two-stage design; and then introduces several novel Bayesian designs, including posterior probability (PrP) and predictive probability (PreP) approaches, and Bayesian optimal Phase II design (BOP2) and its extensions. Bayesian